Customer concentration
Three customers represented 43.5% of revenue in fiscal 2025, so losing a major account would materially affect results.
- Scope
- Major pharmaceutical, biotech and medical device clients
- Materiality
- high
Pharma-Bio Serv, Inc.
Pharma-Bio Serv, Inc. is a Puerto Rico-based technical compliance consulting firm organized in Delaware and serving clients in the United States, Puerto Rico, Europe and, to a lesser extent, Brazil. It provides regulatory affairs, quality, validation, technology transfer, engineering, project management and process support services to regulated life-science and allied industries.
−6,4 %
32,3 %
−1,1 %
−5,3 %
7.70
7.70
| % | |
|---|---|
| Regulatory compliance consulting | 35% Advisory services that help clients meet FDA and international regulatory requirements. |
| Validation and qualification services | 25% Testing, documentation and qualification work for regulated facilities, systems and processes. |
| Technology transfer services | 15% Support for transferring products, processes and methods between sites or organizations. |
| Engineering and project management | 15% Technical project execution, process support and implementation services for client operations. |
| Quality and process support | 10% Ongoing quality assurance, compliance remediation and operational support services. |
The company serves pharmaceutical, biotechnology, medical device, chemical, cosmetic and food manufacturers, plus...
- Pharmaceutical manufacturersprimary
Buy regulatory, validation and technology-transfer services to support manufacturing and compliance.
- Biotechnology companiesprimary
Buy quality, process and regulatory support for development and production environments.
- Medical device companiesprimary
Buy validation, qualification and compliance consulting for regulated operations.
- Chemical manufacturerssecondary
Buy technical compliance and process support for regulated production activities.
- Cosmetics, food and allied products companiessecondary
Buy compliance and technical support where product and facility regulations apply.
Pharma-Bio Serv is headquartered in Puerto Rico and operates across Puerto Rico, the United States and Europe, with a...
- •Headquartered in Puerto Rico, which is a core operating base
- •Puerto Rico is a major revenue market and client concentration area
- •The United States is another primary market for compliance consulting
- •Europe is an important growth and project market for the company
- •Brazil is a smaller, developing market with limited current presence
The company’s strategy is to deepen relationships with large regulated manufacturers by delivering specialized...
01
Expand geographic reachmedium-term
Broader market coverage reduces dependence on any one region and opens more client opportunities.
02
Strengthen technical talent baseshort-term
The business depends on specialized consultants with regulated-industry expertise.
03
Increase account penetrationshort-term
Larger existing customers can generate recurring project opportunities and higher utilization.
The business is exposed to customer concentration, since a small number of clients can account for a large share of...
Regulatory change risk
The company sells services that are driven by FDA and international compliance requirements.
- Scope
- Pharmaceutical, biotechnology, medical device and chemical industries
- Materiality
- high
Competitive pressure
The market includes local, national and international consulting firms, some with greater resources.
- Scope
- Puerto Rico, United States and Europe
- Materiality
- medium
Macroeconomic and industry cyclicality
Client spending on compliance projects can slow when inflation, interest rates or industry consolidation affect investment decisions.
- Scope
- Life-science manufacturing markets
- Materiality
- medium
Project revenue timing
Affects revenue comparability across periods
Allowance for credit losses
Affects bad debt expense and net receivables
Foreign exchange on intercompany balances
Affects other income, net
Income taxes and valuation allowance
Affects tax expense and deferred tax balances
Leases
Affects leverage and operating expense presentation
: 29.4.2026